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Abstract: The aim of this study was to explore the optimal therapeutic dose and time 
window of picroside II for treating cerebral ischemic injury in rats according to the 
orthogonal test. The middle cerebral artery occlusion (MCAO) models were established by 
intraluminally inserting a thread into middle cerebral artery (MCA) from left external 
carotid artery (ECA). The successful rat models were randomly divided into 16 groups 
according to the orthogonal layout of [L16(4
5)] and treated by injecting picroside II 
intraperitoneally with different doses at various times. The neurological behavioral 
function was evaluated by Bederson’s test and the cerebral infarction volume was 
measured by tetrazolium chloride (TTC) staining. The expressions of neuron specific enolase 
(NSE) and neuroglial mark-protein S-100 were determined by immunohistochemisty assay. 
The results indicated that the optimal compositions of the therapeutic dose and time 
window of picroside II in treating cerebral ischemic injury were ischemia 1.5 h with 
20 mg/kg body weight according to Bederson’s test, 1.0 h with 20 mg/kg body weight 
according to cerebral infarction volume, 1.5 h with 20 mg/kg body weight according to the 
expressions of NSE and S-100 respectively. Based on the principle of the minimization of 
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medication dose and maximization of therapeutic time window, the optimal composition of 
the therapeutic dose and time window of picroside II in treating cerebral ischemic injury 
should be achieved by injecting picroside II intraperitoneally with 20 mg/kg body weight at 
ischemia 1.5 h. 
Keywords: picroside II; cerebral ischemia; therapeutic dose; time window; NSE; S-100; rats  
 
1. Introduction  
Cerebral ischemic reperfusion injury is a pathological process resulting from many factors, such as 
excitatory amino acids releasing, oxidative stress, calcium ion overloading, inflammatory reaction, 
apoptosis, etc. [1–3]. Neuron-specific enolase and neuroglial mark-protein S-100 can reflect the degree 
of cerebral injury [4–6]. The former study of cell culture proved that pcroside II could lessen the injury 
to PC12 induced by H2O2 and raise the cell survival rate [7–12]. Some animal experiments proved that 
picroside II could inhibit apoptosis and the expression of related inflammatory factors in ischemic 
penumbra after ischemic reperfusion injury [13–15]. The authors’ former experiments indicated that 
picroside II could reduce the degradation of the substrate, poly ADP-ribose polymerase (PARP) with 
catalytic activity, by inhibiting the expression toll-like receptor 4 (TLR4), nuclear transcription factor κB 
(NFκB), tumor necrotic factor α (TNFα) and Capase-3, and make PARP to utilize the remanent energy 
in the cells of ischemic penumbra to repair the nerve cells which have the reversibility of refreshing, so 
that to inhibit the ischemic injury leading to the apoptosis [16–23]. However, in these experiments, the 
rats were treated by injecting picroside II with a simple dose (20 mg/kg) at a simple time after 
ischemia (2 h) from tail vein. In this study, the authors aimed to explore the optimal therapeutic dose 
and time window of picroside II injecting intraperitoneally in cerebral ischemic injury in rats according 
to the design principle of orthogonal test. 
2. Results and Discussion 
2.1. Neurobehavioral Deficit Score 
After treated by picroside II, each rat showed behavioral defect at different degree. By the analysis 
of software of SPSS (set α = 0.05), the probability of significant interaction of independent variable 
was 0.46 > 0.05 (Table 1), and there was no interaction between administering drug time and 
administering drug dose. From the result of analysis of variance, the significant probability of each 
independent variable was P  = 0.02 < 0.05. Therefore, medication time and dose have significant 
influence on recovery of neurological function. All data are analyzed by the statistical mean of   
two-way ANOVA (analysis of variance) and LSD (least significant difference) value, the analytic 
results showed that there was no significant differences between administering drug at ischemia 1 h 
(A1) and 1.5 h (A2), and between administering drug at ischemia 2 h (A3) and 2.5 h (A4), P > 0.05. 
There was no significant deviation between administering drug doses of 5 mg/kg (B1) and 10 mg/kg 
(B2) and between administering drug doses of 20 mg/kg (B3) and 40 mg/kg (B4), P > 0.05. In addition, 
there was a significant differences between each other for the rest groups, P < 0.05, so that the better Int. J. Mol. Sci. 2012, 13  
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composition of the therapeutic dose and time window of picroside II were A1B3, A1B4, A2B3, A2B4. 
Considering the principles of medication dose minimization and therapeutic time maximization, it is 
presumed that A2B3 is the best composition, namely the best therapeutic time window and the best 
therapeutic dose of picroside II is ischemia 1.5 h with 20 mg/kg body. 
Table 1. Analysis of variance about neurological function defect. 
Variation source  SS  df  MS  F  P 
Time 3.187  3  1.06  17  0.02 
Dose 3.187  3  1.06  17  0.02 
Time*Dose  0.188  3 0.63 1 0.45 
Error 0.375  6  0.63     
The significant probability of independent variable time was P = 0.02 < 0.05; the significant 
probability of independent variable dose was P = 0.02 < 0.05; the significant probability of 
independent variable interaction was P = 0.45 > 0.05. 
2.2. Volume of Cerebral Infarction  
After treated by picroside II, all rats showed an infarction volume at different degree in the area 
supplied by middle cerebral artery with TTC staining. According to the analysis with software of SPSS 
(set α = 0.05), the significant probability of the interaction of independent variables is 0.23 > 0.05, so 
there is no interaction between medication time and therapeutic dose (Tables 2 and 3). The result of 
ANOVA showed that the significance probability of every independent variable was P < 0.01, which 
indicated the medication time and therapeutics dose of picroside II influenced on cerebral infarction 
volume significantly. All data are analyzed by the statistical mean of two-way ANOVA and LSD value. 
It is concluded that there was significant deviation between each other of medication time (P < 0.05), 
no significant deviation between therapeutic dose 20 mg/kg (B3) and 40 mg/kg (B4) (P > 0.05), and 
there was a significant deviation between the rest combination, P  < 0.05. Therefore, the better 
combination of medication time and therapeutic dose were A1B3 or A1B4. According to the principles 
of the minimization of medication dose and maximization of therapeutic time, it is presumed that 
A1B3 is the best composition group, i.e., the best therapeutic time window and the best therapeutic 
dose of picroside II is ischemia 1 h with 20 mg/kg body. 
Table 2. The infarction volume of tetrazolium chloride (TTC) staining. 
Drug Dose  Ischemia 1.0 h  Ischemia 1.5 h Ischemia 2.0 h Ischemia 2.5 h
5  mg/kg  69.05 73.00 73.40 75.50 
10  mg/kg  66.20 71.50 72.10 74.30 
20  mg/kg  64.90 69.30 71.60 73.90 
40  mg/kg  64.50 68.90 70.80 72.00 Int. J. Mol. Sci. 2012, 13  
 
 
2554
Table 3. ANOVA of cerebral infraction volume. 
Variation source  SS  df  MS  F  P 
Time 130.46  3  43.49  150.30  0.00 
Dose 30.32  3  10.11  34.93  0.00 
Time*Dose 1.67 3  0.56  1.92  0.23 
Error 1.74  6  0.29     
The significant probability of independent variable time was P  = 0.00 < 0.05; the significant 
probability of independent variable dose was P  = 0.00 < 0.05; the significant probability of 
independent variable interaction was P = 0.23 > 0.05. 
2.3. Expression of NSE Protein 
The immunohistochemisty staining shows that NSE in brain tissue expressed at different degrees, 
and mainly in cytoplasm with yellow or brown colors. The significance probability of the interaction 
of independent variables (the number of positive cells) is 0.78 > 0.05, so there is no interaction 
between medication time and therapeutics dose (Tables 4 and 5). The result of ANOVA showed that 
the significance probability of every independent variable is less than 0.01, which proved that 
medication time and therapeutic dose of picroside II could significantly influence the expression of 
NSE. All data are analyzed by the statistical mean of two-way ANOVA and LSD value, it is concluded 
that there was a significant deviation of NSE expression between each medication time (P < 0.05), 
while no significant deviation between 20 mg/kg (B3) and 40 mg/kg (B4) (P > 0.05), but there was 
significant deviation between the rest therapeutic dose combination (P  < 0.05). So the better 
combination of medication time and therapeutics dose is A1B3 or A1B4. Considering the 
minimization of medication dose and maximization of therapeutic time, it is presumed that A1B3 is the 
best combination, namely the best therapeutic time window and the best therapeutic dose of picroside II 
is ischemia 1.0 h with 20 mg/kg. 
Table 4. The expression positive cells of neuron specific enolase (NSE). 
Drug Dose  Ischemia 1.0 h  Ischemia 1.5 h Ischemia 2.0 h Ischemia 2.5 h
5  mg/kg  36.20 38.33 39.90 41.00 
10  mg/kg  35.00 36.90 37.55 38.00 
20  mg/kg  34.33 35.55 36.80 37.60 
40  mg/kg  34.20 35.60 36.20 37.20 
Table 5. ANOVA of positive cells of NSE. 
Variation source  SS  df  MS  F  P 
Time 27.497  3  9.17  39.39  0.00 
Dose 22.928  3  7.64  32.85  0.00 
Time*Dose 0.253 3  0.08  0.36  0.78 
Error 1.649  6  0.23     
The significant probability of independent variable time was P  = 0.00 < 0.05; the significant 
probability of independent variable dose was P  = 0.00 < 0.05; the significant probability of 
independent variable interaction was P = 0.78 > 0.05.  Int. J. Mol. Sci. 2012, 13  
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2.4. Expression of S-100 Protein 
The immunohistochemial stain shows the expression of S-100 in brain tissue was at different degree 
and mainly in cytoplasm. The significance probability of the interaction of independent variables   
(the number of positive cells) is 0.35 > 0.05, so there is no interaction between medication time and 
therapeutic dose (Tables 6 and 7). The result of ANOVA showed that the significance probability of 
every independent variable is smaller than 0.01, which suggested that the medication time and 
therapeutic dose of picroside II could significantly influence on S-100 expression. All data are 
analyzed by the statistical mean of two-way ANOVA and LSD value. It is concluded that there was no 
significant deviation of S-100 expression between ischemia 1 h (A1) and ischemia 1.5 h (A2), also 
ischemia 1.5 h (A2) and 2 h (A3) (P > 0.05), while there was a significant deviation between the rest 
combination (P < 0.05). Although no significant deviation between therapeutic dose 5 mg/kg (B1) and 
10 mg/kg (B2), or 20 mg/kg (B3) and 40 mg/kg (B4) (P > 0.05), there was a significant deviation 
between the rest combination (P < 0.05). So the better combination of medication time and therapeutic 
dose is A1B3 or A1B4 or A2B3 or A2B4. Considering the minimization of medication dose and 
maximization of therapeutic time, it is presumed that A2B3 is the best combination, namely the   
best therapeutic time window and the best therapeutic dose of picroside II is ischemia 1.5 h with  
20 mg/kg body. 
Table 6. The expression positive cells of S-100. 
Drug Dose  Ischemia 1.0 h  Ischemia 1.5 h Ischemia 2.0 h Ischemia 2.5 h
5  mg/kg  43.88 45.00 45.90 46.00 
10  mg/kg  40.90 44.50 45.10 45.70 
20  mg/kg  37.06 38.25 40.00 44.60 
40  mg/kg  36.03 37.60 39.00 44.00 
Table 7. ANOVA of positive cells of S-100. 
Variation source  SS  df  MS  F  P 
Time 66.09  3  22.03  11.36  0.01 
Dose 106.18  3  35.39  18.26  0.01 
Time*Dose 7.69 3  2.56  1.32  0.35 
Error 19.00  6  1.94     
The significant probability of independent variable time was P  = 0.01 < 0.05; the significant 
probability of independent variable dose was P  = 0.01 < 0.05; the significant probability of 
independent variable interaction was P = 0.35 >0.05.  
2.5. Discussion 
Orthogonal layout can balance sampling in the changing range of variable factors, and can enhance 
the representation of each test with minimum animal number and test times. Orthogonal layout has 
characteristics of balanced scattering, which satisfies some prerequisites of a comprehensive test, 
shortened test cycle and elevated test efficiency to achieve a better test aim. In this paper, the authors 
applied orthogonal layout to design roundly, compared synthetically with statistical analysis to obtain a Int. J. Mol. Sci. 2012, 13  
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better therapeutic schedule to get the best treatment effectiveness with a small number of tests. For 
statistical analysis of the orthogonal test, we chose 2-way ANOVA. 
In this experiment, the neurological behavioral function was evaluated by Bendeson’s test to judge 
the therapeutic effect of picroside II on cerebral ischemic injury, TTC staining was observed and 
calculate the cerebral infarction volume to indicate the severity of cerebral ischemic injury. The 
neuroglial mark-protein S-100 [24–26] and the neuron-specific enolase (NSE) are sensitive indexes to 
evaluate cerebral ischemic injury [27,28]. NSE is a kind of acidic soluble protein only existing in 
nervous tissue. According to their three subunits with different immunity, enolases are divided into 
five kinds of isozymes as follows: type αα, ββ, γγ, αβ and αγ, of which type γγ exists specially in nerve  
cells and being named as NSE. Enolases participate in the metabolism of glucolysis, catalysis   
α-phosphoglyceric acid into enolphosphopyruvate. S-100 protein is an acidity calcium-binding protein, 
not simple protein but boodle of micromolecule protein with α and β subunits, of which the S-100 with 
β-subunit particularly exist in nerve tissue, and mainly in gliacyte. S-100 is a kind of intercellular  
calcium-receptor protein and regulates energy metabolism, promotes axon growth and gliocyte 
proliferation, stabilizes internal environment of calcium ion, etc. In the physiological circumstances, 
the contents of NSE and S-100 in brain tissue and serum are seldom and increase after brain ischemic 
injury to release in to the blood circulation because of cerebral ischemia injuring the blood-brain 
barrier. NSE and S-100 are neurochemistry markers reflecting the severity of brain tissue damage [25], 
so it could reflect the neuroprotective effects of picroside II on cerebral ischemia by detecting the 
contents of NSE and S-100 in brain tissue and serum.  
In this experiment, the authors designed four time points at 1 h, 1.5 h, 2 h and 2.5 h after brain 
ischemic injury, and inject intraperitoneally picroside II with four therapeutic doses of 5 mg/kg,   
10 mg/kg, 20 mg/kg and 40 mg/kg. The experiment was carried out according to orthogonal table of 
[L16(4
5)] to explore the best therapeutic dose and best time window of picroside II in treating cerebral 
ischemic injury by neurological faction scale, TTC staining to measure cerebral infarction volume and 
the expressions of NSE and S-100, etc. The results indicated that there is a significant difference 
between administering drug time and therapeutic drug dose of picroside II in influencing the multiple 
comparison of statistical analysis showed that the best combination is not with accordant by different 
indexes. Considering minimization of medication dose and maximization of therapeutic time window, 
it is suggested the best choose of A1B3 composition, or the best therapeutic time window is at 1.0 h 
after ischemia and the best therapeutic dose of picroside II is 20 mg/kg. Because the mechanism of 
cerebral ischemic injury is very complicated and only four indexes was observed in this experiment, 
the results could not possibly all be right. So the effect and mechanism of picroside II and the golden 
evaluating indexes need to be further studied in further experiments. 
3. Experimental Section 
3.1. Animal Model of MCAO 
Adult healthy male Wistar rat, SPF grade, weight 240–260 g, were supplied by the Experiment 
Animal Center of Qingdao Drug Inspection Institute (SCXK (LU) 20090100). The local legislation for 
ethics of experiment on animals and guidelines for the care and use of laboratory animals were Int. J. Mol. Sci. 2012, 13  
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followed in all animal procedures. This experiment was approved by the Ethics Committee of Qingdao 
University Medical College (No. QUMC 2011-09). All animals were acclimatized for 7 days and 
allowed free access to food and water in a room temperature (23 ± 2 °C) and humidity-controlled 
housing with natural illumination and absolute diet at preoperative 12 h before operation. The rats 
were anesthetized by injecting intraperitoneally 100 g/L chloral hydrate (300 mg/kg) and fixed in 
supine position to conduct aseptic operation. The middle cerebral artery occlusion (MCAO) model was 
established by inserting intraluminaly a monofilament suture from the left external-internal carotid 
artery (ECA-ICA) into the middle cerebral artery (MCA) for cerebral ischemia [29]. Core body 
temperature was checked by a rectal probe and maintained at 36–37 °C using a homeothermic blanket 
control unit (Qingdao Apparatus, China) during and after the surgery operation. The successful model 
rats showed left Horner’s sign, right forelimb flexing and circling rightward as running.  
3.2. Orthogonal Experimental Design 
Sixteen successful MCAO rat models were internalized into the experiment and divided randomly 
according to the principle of orthogonal experimental design of [L16(4
5)] consisting of two impact 
factors with four impact levels (Table 8). The impact factor A is the therapeutic time widow designed 
four levels: 1.0 h, 1.5 h, 2.0 h, 2.5 h after ischemia. The impact factor B is the therapeutic drug dose 
which has four levels as follows: 5 mg/kg, 10 mg/kg, 20 mg/kg and 40 mg/kg body weight (Table 5).  
Table 8. Orthogonal experimental design of [L16(4
5)]. 
Therapeutic dose 
Ischemia  
1.0 h (A1) 
Ischemia 
1.5 h (A2)
Ischemia 
2.0 h (A3)
Ischemia  
2.5 h (A4) 
Therapeutic 
dose 
5 mg/kg (B1)  1.0 × 5  1.5 × 5  2.0 × 5  2.5 × 5  5 mg/kg (B1) 
10 mg/kg (B2)  1.0 × 10  1.5 × 10  2.0 × 10  2.5 × 10  10 mg/kg (B2)
20 mg/kg (B3)  1.0 × 20  1.5 × 20  2.0 × 20  2.5 × 20  20 mg/kg (B3)
40 mg/kg (B4)  1.0 × 40  1.5 × 40  2.0 × 40  2.5 × 40  40 mg/kg (B4)
3.3. Treatment Methods 
Picroside II (Tianjin Kuiqing Medical Technology Co., Ltd., CAS No: 39012-20-9, purity >98%) 
was  diluted into 1% solution with 0.1 mol/L PBS and injected intraperitoneally according to the 
corresponding designed doses in the orthogonal layout [L16(4
5)]. After treatment for 24 h, the rats were 
killed to detect the corresponding indexes. 
3.4. Observation Indexes 
3.4.1. Neurological Defect Test  
After treatment with picroside II, the neurological behavioral function scales were performed by 
Bederson’s test [30] in each rats. The higher the score, the more severe the neurological function 
defect. Score 0: no behavioral deficiency; Score 1: forelimb buckling (the tail lifting-suspension test 
positive); Score 2: lateral thrust resistance decreased (lateral thrust test positive) and forelimb buckling, 
no circling; Score 3: the same as midrange behavior and circling spontaneously. Int. J. Mol. Sci. 2012, 13  
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3.4.2. The Cerebral Infarction Volume 
After treatment with picroside II, all rats were anesthetized with 100 g/L chloral hydrate (300 mg/kg) 
and then the brain was take out completely to be cut five coronal sections of 2 mm thickness backward 
from the Bregma. Five coronal sections were put into 20 g/L TTC phosphate buffer at 37 °C and then 
fixed in 40 g/L poly-formaldehyde. The normal brain tissues showed red and infarct tissue is white 
(Figure 1). The infarct volume is determined by Adobe PhotoShop CS after taking a photograph, and 
expressed as the percentage of the brain infarct size and homonymy brain hemisphere (%). 
Figure 1. The cerebral infarction volume. The normal brain tissues showed red and infarct 
tissue white by TTC staining. 
 
3.4.3. Immunohistochemisty  
After treatment with picroside II, total of rats were anesthetized with 100 g/L chloral hydrate   
(300 mg/kg) and fixed with 40 g/L poly-formaldehyde from cardiac perfusion to take out the brain 
completely. The brain was dehydrated by gradient ethanol, cleared by xylene, embedded in paraffin 
and sliced backward from optic chiasma into pieces of thickness 5 µm. Then adhered those slices to 
the sections prepared with poly-L-lysine, and finally stored at 4 °C. Rabbit anti-rat NSE and S-100 
moloclonal antibodies, SABC immunohistochemisty kit and DAB chromogenic liquor were provided 
by Boster Biological Company, Wuhan, China. The paraffin section were deparaffinized according to 
directions, then colored by DAB and observed under light microscope to count the positive cells with 
brown granules in cytoplasm. And the slides with the addition of 0.01 mmol/L PBS (containing 1:200 
non-immunity animal serum), instead of primary antibody, showed no response. Five serial section 
(1mm backward from optic chiasma) of each rat were randomly chosen and observed five visual fields 
of cortical area under light microscope (400 times) to count the number of positive cells of every visual 
fields and expressed as mean ± standard error ( x  ± s) (Figure 2). 
Figure 2. The expressions of NSE in cortex (A) and S-100 in hippocampus (B). The 
immunochemical positive cells showed brown granules in cytoplasm, bar 25 µm. 
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3.5. Statistical Analysis 
SPSS 17.0 software was used for data statistical analysis (Table 9). According to the result,   
multi-group comparison was made by analysis of orthogonal test whether different level of administrating 
time and therapeutic dose had significant deviation or not, and whether their interaction on each 
detected index had significant deviation or not, meanwhile to explore the best therapeutic drug dose 
and the therapeutic time window. Values were considered to be significant when P was less than 0.05. 
Table 9. [L16(4
5)] orthogonal layout and the results of infarction volume. 
Test NO. 
Rank NO.  Infarction 
volume  A B  C D  E 
1 1  1  1  1  1  69.05 
2 1  2  2  2  2  66.20 
3 1  3  3  3  3  64.90 
4 1  4  4  4  4  64.50 
5 2  1  2  3  4  73.00 
6 2  2  1  4  3  71.50 
7 2  3  4  1  2  69.30 
8 2  4  3  2  1  68.90 
9 3  1  3  4  2  73.40 
10 3  2  4  3  1  72.10 
11 3  3  1  2  4  71.60 
12 3  4  2  1  3  70.80 
13 4  1  4  2  3  75.50 
14 4  2  3  1  4  74.30 
15 4  3  2  4  1  73.90 
16 4  4  1  3  2  72.00 
I 264.65  290.95 284.15    1132.95 
II 282.70  284.10 283.90      
III 287.90  279.70 281.50      
IV 295.70  276.20 281.40      
SS 130.46  30.32  1.677      
4. Conclusions 
This study suggested the optimal composition of the therapeutic dose and time window of picroside II 
in treating cerebral ischemic injury should be injecting picroside II intraperitoneally with 20 mg/kg 
body weight at ischemia 1.5 h after considering the minimization of medication dose and maximization 
of therapeutic time. 
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